However, the overall effects of dapagliflozin on atherosclerosis in DM and the potential benefits involved, for example, their effects on IL-1β and IL-18 cytokines and NLRP3 inflammasome systems, have not been evaluated. This evidence concerns the gene NLRP3 and diabetes mellitus.